Cargando…

2817. Outcomes of Timely vs. Delayed Meropenem/Vaborbactam Treatment of Infections with CRE among Adults Hospitalized in the US, 2019-2021

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) represent an urgent threat. Mortality rates associated with this pathogen approach 80%. Timely treatment of serious infections, even with highly resistant organisms, among hospitalized patients improves the chances of survival. We explored whet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zilberberg, Marya D, Nathanson, Brian H, Redell, Mark, Sulham, Kate, Shorr, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678142/ http://dx.doi.org/10.1093/ofid/ofad500.2428

Ejemplares similares

2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021
por: Zilberberg, Marya D, et al.
Publicado: (2023)

1430. Descriptive Epidemiology of Emergency Department Visits with cUTI in the US, 2012-2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

1461. Antimicrobial Susceptibility Patterns of Common Complicated Urinary Tract Infection Pathogens in US Hospitals, 2013–2018
por: Zilberberg, Marya, et al.
Publicado: (2019)

Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013–2018: a retrospective cohort study
por: Zilberberg, Marya D., et al.
Publicado: (2021)

1420. Descriptive Epidemiology of UTI Hospitalizations in the US, 2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

1427. Healthcare Resource Utilization During Hospitalizations with UTI in the US, 2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

1455. Epidemiology, Empiric Treatment, and Outcomes Among Hospitalized Patients With Complicated Urinary Tract Infections in the United States, 2013–2018
por: Zilberberg, Marya, et al.
Publicado: (2019)

30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset Acinetobacter baumannii pneumonia or sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016–2018
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018
por: Zilberberg, Marya D, et al.
Publicado: (2022)

1314. Descriptive Epidemiology of 30-day Readmissions among Survivors of Hospitalization with Bacterial Nosocomial Pneumonia in the US, 2012-2019
por: Zilberberg, Marya, et al.
Publicado: (2021)

Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2017)

Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis
por: Zilberberg, Marya D., et al.
Publicado: (2016)

Descriptive Epidemiology and Outcomes of Patients with Short Stay Hospitalizations for the Treatment of Congestive Heart Failure in the US
por: Zilberberg, Marya D, et al.
Publicado: (2023)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections
por: Lai, Chih-Cheng, et al.
Publicado: (2019)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Descriptive epidemiology of hospitalized patients with bacterial nosocomial pneumonia who experience 30-day readmission in the US, 2014–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Examining the Burden of Potentially Avoidable Heart Failure Hospitalizations
por: Zilberberg, Marya D, et al.
Publicado: (2023)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures
por: Squires, Kevin M, et al.
Publicado: (2023)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
por: Castanheira, Mariana, et al.
Publicado: (2023)

The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012–2019
por: Zilberberg, Marya D., et al.
Publicado: (2021)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
por: Carvalhaes, Cecilia G., et al.
Publicado: (2020)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

1676. PK, Safety and Tolerability of VABOMERE(®) (meropenem-vaborbactam) in Infants, Children and Adolescents
por: Bokesch, Paula M, et al.
Publicado: (2023)

Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014–2019
por: Zilberberg, Marya D., et al.
Publicado: (2022)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
por: Trang, M., et al.
Publicado: (2021)

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date
por: Herald, Fischer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8tp1v220s0tv0uf87nkhllipsj